Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Avacta Group plc ( (GB:AVCT) ) has shared an update.
Avacta Group PLC announced the appointment of Brian Hahn as Chief Financial Officer, bringing over 25 years of experience in financial operations within the biopharmaceutical industry. Hahn’s extensive background in leading successful IPOs, strategic planning, and capital market engagement is expected to support Avacta’s growth, particularly as it prepares for a potential dual listing on the Nasdaq exchange, enhancing its position in both UK and US markets.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company that develops next-generation peptide drug conjugates (PDC) targeting cancer. Its innovative platforms, pre|CISION® and Affimer®, focus on delivering potent anti-tumor agents directly to tumor sites, aiming to revolutionize cancer treatment by improving patient outcomes and reducing side effects.
YTD Price Performance: 2.00%
Average Trading Volume: 1,638,215
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £186.6M
For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.
